- Research works
- 4 fractional, all time
- Citations
- 5 1.2 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 88% world 28%
Not ranked overall: Targepeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does Targepeutics (United States) publish most on?
By volume in 2022–2025: Toxin Mechanisms and Immunotoxins, HER2/EGFR in Cancer Research, Glioma Diagnosis and Treatment and Chronic Lymphocytic Leukemia Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Toxin Mechanisms and Immunotoxins Immunology 1 works
- 2 HER2/EGFR in Cancer Research Oncology 0 works
- 3 Glioma Diagnosis and Treatment Genetics 0 works
- 4 Chronic Lymphocytic Leukemia Research Genetics 0 works
- 5 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
- 6 CAR-T cell therapy research Oncology 0 works
- 7 Cancer Research and Treatments Biotechnology 0 works
- 8 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
- 9 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 0 works
- 10 Medical Imaging Techniques and Applications Radiology, Nuclear Medicine and Imaging 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Targepeutics (United States)'s research output changed?
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Hershey
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.